China (Mainland)
Diamondsupplier 
99% up by HPLC Nilotinib 641571-10-0 CAS NO.641571-10-0
- Min.Order: 1 Kilogram
- Payment Terms: L/C,D/A,D/P,T/T
- Product Details
Keywords
- Nilotinib 641571-10-0
- Nilotinib
- 641571-10-0
Quick Details
- ProName: 99% up by HPLC Nilotinib 641571-10-0
- CasNo: 641571-10-0
- Molecular Formula: C28H22F3N7O
- Appearance: White or almost white hygroscopic powd...
- Application: API
- DeliveryTime: 7 working days
- PackAge: 25kg per drum
- Port: shanghai/beijing/hangzhou
- ProductionCapacity: 1000 Kilogram/Month
- Purity: 99.9%
- Storage: Normal temperature
- Transportation: normal temperature.
- LimitNum: 1 Kilogram
Superiority
Why is SINOWAY:
1) Specialized in pharmaceutical and healthcare industrial for 34 years.
2) ISO 9001:2015 & SGS audited supplier .
3) Accept various payment terms : T.T 30-60 days.
4) We have warehouse in USA with quickly shipment .
5) We can do different terms of FOB ,CIF/CIP ,DDP ...
Details
|
Product name |
Nilotinib |
|
CAS No. |
641571-10-0 |
|
Molecular Formula |
C28H22F3N7O |
|
Molecular Weight |
529.523 |
|
Quality Standard |
99% up by HPLC |
|
Appearance |
White to pale yellow powder |
Function of Nilotinib
Nilotinib is improved from the molecular structure of imatinib, and has stronger selectivity for BCR-ABL kinase activity, and its inhibitory effect on tyrosine kinase is 30 times stronger than that of imatinib, which can inhibit Kinase activity of imatinib-resistant BCR-ABL mutants, while also inhibiting KIT and PDGFR kinase activities. For the treatment of chronic myeloid leukemia (CML), a life-threatening blood cancer that is refractory to or intolerable to imatinib mesylate. Based on a pivotal Phase II clinical study design evaluating the positive results of oral nilotinib in clinical trials against imatinib mesylate or in patients with Ph+ CML in the slow and accelerated phases of apparent toxicity: High efficacy, good tolerance, and manageable safety.
